Nalaganje...

Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells

The gradual emerging of resistance to imatinib urgently calls for the development of new therapy for chronic myeloid leukemia (CML). The fusion protein Bcr-Abl, which promotes the malignant transformation of CML cells, is mainly located in the cytoplasm, while the c-Abl protein which is expressed in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Li, Qianyin, Huang, Zhenglan, Gao, Miao, Cao, Weixi, Xiao, Qin, Luo, Hongwei, Feng, Wenli
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2017
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5372553/
https://ncbi.nlm.nih.gov/pubmed/28257089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18030537
Oznake: Označite
Brez oznak, prvi označite!